NCT03873246View on ClinicalTrials.gov

Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

February 18, 2019

Primary Completion Date

January 7, 2020

Study Completion Date

January 7, 2020

Conditions
Dry Eye Disease
Interventions
DRUG

OC-01 0.1% 0.6 mg/ml

OC-01 (varenicline) nasal spray: 0.1 % (0.6 mg/ml)

DRUG

OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)

OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)

OTHER

placebo comparator

vehicle control

Trial Locations (1)

Unknown

Mexico City, Mexico City

Sponsors
All Listed Sponsors
lead

Oyster Point Pharma, Inc.

INDUSTRY

NCT03873246 - Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study) | Biotech Hunter | Biotech Hunter